327 related articles for article (PubMed ID: 33439472)
1. Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Tanni KA; Truong CB; Almahasis S; Qian J
BioDrugs; 2021 Mar; 35(2):239-254. PubMed ID: 33439472
[TBL] [Abstract][Full Text] [Related]
2. Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States.
Xue X; Truong B; Qian J
Expert Opin Biol Ther; 2023; 23(8):841-849. PubMed ID: 36892184
[TBL] [Abstract][Full Text] [Related]
3. Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database.
Xue X; Qian J
Expert Opin Drug Saf; 2024 May; ():1-10. PubMed ID: 38680112
[TBL] [Abstract][Full Text] [Related]
4. Author's Reply to Joerg Putzke et al. Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".
Qian J; Truong CB; Tanni KA
BioDrugs; 2021 May; 35(3):375-377. PubMed ID: 33860920
[No Abstract] [Full Text] [Related]
5. Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".
Putzke J; Haughie S; Zou KH; Ranganna GM
BioDrugs; 2021 May; 35(3):373-374. PubMed ID: 33860919
[No Abstract] [Full Text] [Related]
6. Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch.
Sagi S; Anjaneya P; Kalsekar S; Kottke A; Cohen HP
Drug Saf; 2023 Dec; 46(12):1391-1404. PubMed ID: 37902937
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis.
Yang J; Yu S; Yang Z; Yan Y; Chen Y; Zeng H; Ma F; Shi Y; Shi Y; Zhang Z; Sun F
BioDrugs; 2019 Aug; 33(4):373-389. PubMed ID: 31161461
[TBL] [Abstract][Full Text] [Related]
8. Nomenclature and traceability debate for biosimilars: small-molecule surrogates lend support for distinguishable nonproprietary names.
Chao J; Skup M; Alexander E; Tundia N; Macaulay D; Wu E; Mulani P
Adv Ther; 2015 Mar; 32(3):270-83. PubMed ID: 25772256
[TBL] [Abstract][Full Text] [Related]
9. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
[TBL] [Abstract][Full Text] [Related]
11. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
Scavone C; Sessa M; Clementi E; Corrao G; Leone R; Mugelli A; Rossi F; Spina E; Capuano A
BioDrugs; 2018 Dec; 32(6):607-617. PubMed ID: 30341487
[TBL] [Abstract][Full Text] [Related]
12. Biosimilar Use Among 38 ASCO PracticeNET Practices, 2019-2021.
Bourbeau B; Lyman GH; Lei XJ; Jones L; Rosenthal J; Kozlik MM; Oettel KR; Tinger A; Page R
JCO Oncol Pract; 2023 Jul; 19(7):516-522. PubMed ID: 37084324
[TBL] [Abstract][Full Text] [Related]
13. Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System.
Bhardwaja B; Klocke S; Ekinci E; Jackson A; Kono S; Olson KL
BioDrugs; 2022 Jan; 36(1):1-11. PubMed ID: 34817847
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of adverse events associated with filgrastim originator and biosimilar using a spontaneous reporting system database.
Niinomi I; Hosohata K; Oyama S; Inada A; Wakabayashi T; Iwanaga K
Pharmazie; 2020 Apr; 75(4):151-153. PubMed ID: 32295692
[TBL] [Abstract][Full Text] [Related]
15. Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis.
Na H; Kwon SH; Son KH; Baek Y; Kim J; Lee EK
BioDrugs; 2023 Mar; 37(2):205-218. PubMed ID: 36729329
[TBL] [Abstract][Full Text] [Related]
16. Evaluating AE Reporting of Two Off-Patent Biologics to Inform Future Biosimilar Naming and Reporting Practices.
Stergiopoulos S; Getz K
Drug Saf; 2015 Aug; 38(8):687-92. PubMed ID: 26108298
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of biosimilar epoetins in nephrology in the United States.
Fishbane S; Shah HH
Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
Ahmed I; Kaspar B; Sharma U
Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
[TBL] [Abstract][Full Text] [Related]
19. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
Mansell K; Bhimji H; Eurich D; Mansell H
BMC Health Serv Res; 2019 Nov; 19(1):827. PubMed ID: 31718624
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars: Implications for Clinical Practice.
Rifkin RM; Peck SR
J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
